• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Response to US review rules on patent subject matter of traditional Chinese medicine compositions].

作者信息

Liu Pan, Cao Ya-di, Gong Rui-Juan, Liu Wei

机构信息

School of Management, Beijing University of Chinese Medicine, Beijing 100029, China.

出版信息

Zhongguo Zhong Yao Za Zhi. 2018 Feb;43(3):627-630. doi: 10.19540/j.cnki.cjcmm.20171208.003.

DOI:10.19540/j.cnki.cjcmm.20171208.003
PMID:29600632
Abstract

The United States Patent and Trademark Office(USPTO) issued Interim Guidance on Patent Subject Matter Eligibility on December 16, 2014, bringing certain effects to the review rules on patent application of Chinese medicine compositions. Based on the Interim Guidance, cases analysis was used in this paper to analyze the patent subject matter issues of traditional Chinese medicine compositions in the United States. The researches have shown that the application documents should be properly written in the United States when the patent for Chinese medicine compositions is applied, which can improve the probability of authorization.

摘要

相似文献

1
[Response to US review rules on patent subject matter of traditional Chinese medicine compositions].
Zhongguo Zhong Yao Za Zhi. 2018 Feb;43(3):627-630. doi: 10.19540/j.cnki.cjcmm.20171208.003.
2
[Current quality research situation of precious Chinese patent medicine].[名贵中成药的当前质量研究状况]
Zhongguo Zhong Yao Za Zhi. 2008 Feb;33(3):329-33.
3
[Cluster analysis on authorized patents of compound traditional Chinese medicines with different efficacy in 2010].2010年不同功效的中药复方授权专利聚类分析
Zhongguo Zhong Yao Za Zhi. 2012 Aug;37(16):2478-82.
4
[Clinical orientation of post-marketing Chinese patent drugs: an evidence-based practice].[上市后中药专利药的临床定位:循证实践]
Zhong Xi Yi Jie He Xue Bao. 2008 Sep;6(9):887-90. doi: 10.3736/jcim20080902.
5
[Key points for clinical orientation in the secondary development of famous and superior Chinese patent drugs].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Oct;28(10):939-40.
6
[Analyses on positive influence of harmonous development of traditional Chinese medicine compounds' researchs and patent protection].[中药复方研究与专利保护协调发展的积极影响分析]
Zhongguo Zhong Yao Za Zhi. 2012 Jan;37(1):9-12.
7
[Research on patent quality of Chinese listed traditional Chinese medicine enterprises from R&D investment perspective].从研发投入视角看中国上市中药企业专利质量研究
Zhongguo Zhong Yao Za Zhi. 2019 Mar;44(6):1284-1288. doi: 10.19540/j.cnki.cjcmm.2019.0024.
8
[Regional development of patents of traditional Chinese medicine compounds on basis of cluster analysis].基于聚类分析的中药复方专利区域发展研究
Zhongguo Zhong Yao Za Zhi. 2012 Aug;37(16):2472-7.
9
[Application of near-infrared spectroscopy technology in quality control of TCM manufacturing process].近红外光谱技术在中药生产过程质量控制中的应用
Zhongguo Zhong Yao Za Zhi. 2011 Sep;36(17):2433-6.
10
Asian medicine. The new face of traditional Chinese medicine.亚洲医学。中医的新面貌。
Science. 2003 Jan 10;299(5604):188-90. doi: 10.1126/science.299.5604.188.